Adage Capital Partners
CNTA

Adage Capital Partners’s Centessa Pharmaceuticals CNTA Stock Holding History

Adage Capital Partners’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$355M Sell
8,925,010
-2,356,731
-21% -$60.3M 0.55% 25
2025
Q4 		$282M Buy
11,281,741
+1,246,741
+12% +$31.6M 0.43% 37
2025
Q3 		$243M Buy
10,035,000
+1,632,000
+19% +$29M 0.39% 37
2025
Q2 		$110M Buy
8,403,000
+1,449,000
+21% +$18.4M 0.19% 105
2025
Q1 		$100M Buy
6,954,000
+1,834,973
+36% +$30M 0.19% 112
2024
Q4 		$85.7M Buy
5,119,027
+924,027
+22% +$15.3M 0.15% 127
2024
Q3 		$67.1M Buy
4,195,000
+1,070,000
+34% +$13.1M 0.12% 184
2024
Q2 		$28.2M Buy
3,125,000
+875,000
+39% +$8.3M 0.05% 355
2024
Q1 		$25.4M Sell
2,250,000
-646,128
-22% -$6.12M 0.05% 388
2023
Q4 		$23.1M Buy
2,896,128
+65,628
+2% +$440K 0.05% 386
2023
Q3 		$18.3M Buy
2,830,500
+580,500
+26% +$3.97M 0.04% 417
2023
Q2 		$13.9M Buy
+2,250,000
New +$10.7M 0.03% 499

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Adage Capital Partners's CNTA Position: Q1 2026 in Review

Adage Capital Partners reduced its Centessa Pharmaceuticals (CNTA) stake by 21% in Q1 2026, selling an estimated $60.3M and leaving 8,925,010 shares worth $355M. The position accounts for 0.55% of the portfolio, ranked #25.

Adage Capital Partners first reported a position in CNTA in Q2 2023 and has held it in 12 quarters since. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Adage Capital Partners held 8,925,010 shares of Centessa Pharmaceuticals worth $355M as of Q1 2026.
  • Adage Capital Partners sold 2,356,731 Centessa Pharmaceuticals shares in Q1 2026, an estimated $60.3M.
  • Centessa Pharmaceuticals made up 0.55% of Adage Capital Partners's portfolio in Q1 2026, its #25 holding.
  • Adage Capital Partners first reported a position in Centessa Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.